Current studies are showing that micro and macro complications begin at prediabetes.Read More »
The majority of patients with type 2 diabetes fail to maintain glycemic goals over time after initial success with standard interventions.Read More »
Researchers may have found a new way to detect hypertension and diabetes in people with obesity: an alteration in the hypothalamic-pituitary-adrenal (HPA) axis.Read More »
A middle-aged woman, with mild obesity and type 2 diabetes, was hospitalized in the ICU, and the order on her chart was documented "Lispro 90 units at HS," then the "9" was crossed off and a "6" written above it....Read More »
The future could hold more treatment options for patients with type 1 diabetes.Read More »
Can adjunctive therapy over insulin alone solve patient problems with type 1 diabetes?Read More »
Costs vs. Outcomes for Patients With Type 2 Diabetes: The issue of cost in healthcare is a central point in the discussion of the future of medicine. While much is made of the cost of end-of-life care, many of the dollars spent yearly are focused on the treatment of chronic diseases like diabetes. The estimated yearly cost of diabetes care was $245 billion in the U.S. in 2012, the last year for which numbers have been reported. $50 billion of that was related to prescription drug purchases.Read More »
Examining risk for type 2 in patients with genetic dyslipidemia conditions.Read More »
Part 1 of a series on a framework developed by Dr. Bradley Eilerman and Len Testa for recommending medications for treating patients with type 2 diabetes.
A thousand times today, in offices all over America, hospital patients will be diagnosed with type 2 diabetes. When that happens, a healthcare provider has to make a treatment decision of enormous complexity, often with partial information to go on, and in the span of just a few minutes.
Could the visual disturbances that diabetes patients experience be prevented?Read More »